Johnson & Johnson announced acquisition of Tibotec-Virco NV for $320 million in cash and debt
On Mar. 18, 2002, Johnson & Johnson announced an agreement to acquire all of the assets of Tibotec-Virco…
Genomics | NIH | Therapeutics
NIHﾒs All of Us Research program released first genomic dataset of nearly 100,000 whole genome sequences
On Mar. 17, 2022, the National Institutes of Health announced that nearly 100,000 highly diverse whole genome sequences…
Soligenix COVID-19 vaccine, CiVax, boosted neutralizing activity against SARS-CoV-2, including Delta and Omicron
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax (heat stable COVID-19…
Cocrystal Pharma initiated enrollment in phase 1 influenza a study with novel, broad-spectrum, orally administrated antiviral CC-42344
On Mar. 10, 2022, Cocrystal Pharma announced dosing of the first subjects in a Phase 1 clinical trial…
Mandatory masking in schools reduced COVID-19 cases during Delta surge
On Mar. 10, 2022, schools with mandatory masking during the Delta surge had approximately 72% fewer cases of…
IHME reported three times as many deaths worldwide due to COVID-19 than official reports suggested
On Mar. 10, 2022, the Institute for Health Metrics and Evaluation (IHME) reported that more than three times…
Pfizer initiated phase 2/3 study of novel COVID-19 oral treatment in pediatric participants
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of ProteaseInhibition…
Agriculture | Biotechnology | Diagnostics | Disease | Infectious Disease | Influenza | Therapeutics | Vaccine
USDA confirmed highly pathogenic Avian influenza in two backyard flocks in Connecticut and Iowa
On Mar. 2, 2022, the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) confirmed the…
Biotechnology | COVID-19 | FDA | Therapeutics
Sorrento announced FDA authorization to proceed with phase 1 study of Intranasal STI-9199 against Covid-19 viruses
On Mar. 2, 2022, Sorrento Therapeutics announced that it had received clearance from the FDA for its investigational…
Biotechnology | CRISPR | Disease | Genomics | Therapeutics
U.S. patent appeal board ruled against University of California in CRISPR interference
On Feb. 28, 2022, the Patent and Trial Appeal Board of the U.S. Patent and Trademark Office (USPTO)…
Biotechnology | COVID-19 | Pharmaceutical | Therapeutics | Vaccine | WHO
Sorrento announced COVISHIELD antibody strongly neutralized BA.2 Omicron sublineage virus
On Feb. 22, 2022, Sorrento Therapeutics announced that additional preclinical results demonstrate broad spectrum COVISHIELD (STI-9167) neutralizing activity…
The University of Virginia Cancer Center Received NCI Comprehensive Designation
On Feb. 1, 2022, University of Virginia Cancer Center announced it had been awarded a Comprehensive Cancer Center…
Resverlogix expanded phase 2b clinical trial for COVID-19 treatment with first site in Brazil and second in Canada
On Feb. 17, 2022, Resverlogix announced that the first Brazilian site had been initiated for its Phase 2b…
Researchers documented third known case of HIV remission involving stem cell transplant
On Feb. 15, 2022, a woman with HIV who received a cord blood stem cell transplant to treat…
China approved use of Pfizer’s COVID drug Paxlovid
On Feb. 12, 2022, China’s medical products regulator announced that it had given conditional approval for Pfizer’s COVID-19…
Gilead reported phase 2/3 interim data evaluating safety, tolerability and clinical outcomes of Veklury (Remdesivir) in pediatric patients with COVID-19
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
Veklury (Remdesivir) retained antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
Biotechnology | COVID-19 | NIH | Therapeutics
Merck and Ridgeback announced 3.1 million courses of molnupiravir investigational oral antiviral COVID-19 medicine supplied to U.S. Government
On Feb. 8, 2022, Merck and Ridgeback Biotherapeutics announced that a total of 3.1 million courses of molnupiravir,…
Biotechnology | COVID-19 | Influenza | Plague | Therapeutics
NIAID Pandemic Preparedness Plan targeted ‘prototype’ and priority pathogens
On Feb. 2, 2022, NIAID scientists announced the new Pandemic Preparedness Plan aimed to support critical basic and…
Study of Penn patients with decade-long leukemia remissions after CAR T cell therapy revealed new details about persistence of personalized ‘Living Drug’ cells
On Feb. 2, 2022, a new analysis of the first two patients treated in a clinical trial with…
Artificial Intelligence | Biotechnology | CRISPR | Genomics | Life Science History | Medicine | NIH | Non-Profit Research | Therapeutics | Vaccine
Cancer MoonShot program reignited
On Feb. 2, 2022, President Biden announced a reignition of the Cancer Moonshot, that highlighted new goals: to…
Merck and Ridgeback’s Molnupiravir, investigational antiviral COVID-19 medicine, demonstrated activity against Omicron variant
On Jan. 28, 2022, Merck and Ridgeback Biotherapeutics announced data from six preclinical studies demonstrating that molnupiravir, an…
Cocrystal Pharma selected two lead antiviral drug candidates for COVID-19 oral drug program
On Jan. 27, 2022, Cocrystal Pharma announced that it had selected two investigational novel antiviral drug candidates for…
International research team found nine new coronavirus species
On Jan. 26, 2022, a former University of British Columbia post-doctoral research fellow led an international research team…
Biotechnology | Cartoons - Original | CRISPR | Disease | Genomics | Life Science History | Therapeutics
Evolution of CRISPR
The Evolution of CRISPR illustrates its climb out of the primordial ocean on the backs of eukaryotic cells…
New landmark Nature study provided long-sought mechanistic link between EBV and Multiple Sclerosis
On Jan. 24, 2022, Atara Biotherapeutics, a leader in T-cell immunotherapy, announced that it had leveraged its novel…
Biotechnology | COVID-19 | NIH | Therapeutics
‘Ultrapotent’ antibodies neutralized SARS-CoV-2 variants in NIAID study
On Jan. 20, 2022, scientists from the National Institute of Allergy and Infectious Diseases (NIAID) announced that they…
Oral immunotherapy induced remission of peanut allergy in some young children
On Jan. 20, 2022, a clinical trial funded by the National Institutes of Health found that giving peanut…
Merck and Ridgeback announced supply agreement with UNICEF for molnupiravir, investigational oral antiviral COVID-19 medicine
On Jan. 18, 2022, Merck and Ridgeback Biotherapeutics announced the signing of a long-term supply agreement with the…
Positive results of Pfizer’s phase 3 study exploring co-administration of PREVNAR 20 with Pfizer-BioNTech COVID-19 vaccine released
On Jan. 12, 2022, Pfizer announced positive top-line results from a Phase 3 study describing the safety and…